Skip to main content

Bright Minds Biosciences Inc.

corporate_fare Company Profile

Bright Minds Biosciences Inc.

DRUG·NASDAQ·Life Sciences·CIK 0001827401

Bright Minds Biosciences Inc. is a biotechnology company focused on developing therapeutic treatments for severe and life-altering diseases in the United States. The company's portfolio includes 5-HT2 Receptors, which are serotonin agonists designed to address epilepsy and various neuropsychiatric disorders. A key product, BMB-101, has successfully completed a Phase 1 trial for an undisclosed seizure disorder and is currently undergoing Phase 2 clinical trials for developmental and epileptic encephalopathies and absence epilepsies. Additionally, Bright Minds Biosciences is developing BMB-201 and BMB-202 for neuropsychiatric and neurology indications. Another product in development is BMB-105, a 5-HT2C agonist intended to treat Prader Willi Syndrome. The company collaborates with Firefly Neuroscience, Inc. to analyze electroencephalogram (EEG) data within its BREAKTHROUGH study. Bright Minds Biosciences Inc. was established in 2017 and operates from its headquarters in New York, New York.

Bright Minds Biosciences Inc. (NASDAQ:DRUG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for DRUG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-02, rated 9/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for DRUG spans 6-K, 424B5, FWP.

Recent high-impact activity:

  • FDA Partial Clinical Hold Halts Bright Minds' U.S. Phase 2 DEE Trial of BMB-101
  • FDA Partial Hold Halts U.S. Phase 2 Pediatric Epilepsy Trial; Shares Plunge 55%
  • Bright Minds Biosciences Reports Positive Phase 2 BMB-101 Data & Secures $257M Capital for Pipeline Advancement
  • Bright Minds Biosciences Closes $175M Public Offering at Premium to Market Price
  • Bright Minds Biosciences Secures $175M Public Offering to Fund Clinical Trials

Financial Snapshot

Fiscal year ended September 30, 2025
Net Income
-$12.23M
Op. Cash Flow
-$8.69M
Cash & Equivalents
$55.4M
Debt / Equity
0.00×
Source: 40-F · filed 2025-12-23 · accession 0001437749-25-038729

Short Interest & Short Volume

7.91 days to cover

FINRA reported short interest of 801,241 shares in DRUG as of the October 30, 2026 settlement, a 3.4% decrease from the prior period — about 7.9 days to cover at its recent average daily volume. On November 19, 2026, 33.6% of DRUG volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)801,241 shares as of October 30, 2026
Change vs prior period▼ 3.4%
Days to cover7.91 at avg daily volume of 101,302
Daily short volume (FINRA facilities)33.6% of 54,431 shares on November 19, 2026
5-day average short volume46.8%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Insider Transactions

DRUG files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

Browse all tickers starting with D →
$20.51 -0.93% today
52-week range · as of 2026-11-02 $18.9 – $123.75
Market cap
$202.3M
Volume
69.4K (0.3× avg)
3-mo avg 238.7K
Live data · 2026-11-20 17:21 UTC · Market open

show_chartPrice Chart

Loading chart...

feed DRUG - Latest Insights

DRUG
Nov 02, 2026, 4:30 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $24.54
Real-time Price: $20.51 info
Change: -$4.03 (-16%) info
Market Cap: $202.295M info
DRUG
Nov 02, 2026, 10:00 AM EST
Source: Benzinga
Importance Score:
9
Price at Filing: $20.34
Real-time Price: $20.51 info
Change: +$0.1683 (+0.83%) info
Market Cap: $202.295M info
DRUG
May 19, 2026, 6:15 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $74.54
Real-time Price: $20.51 info
Change: -$54.03 (-72%) info
Market Cap: $202.295M info
DRUG
Jan 09, 2026, 4:11 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $86.75
Real-time Price: $20.51 info
Change: -$66.24 (-76%) info
Market Cap: $202.295M info
DRUG
Jan 08, 2026, 7:32 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $90.01
Real-time Price: $20.51 info
Change: -$69.50 (-77%) info
Market Cap: $202.295M info
DRUG
Jan 08, 2026, 7:02 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $90.01
Real-time Price: $20.51 info
Change: -$69.50 (-77%) info
Market Cap: $202.295M info
DRUG
Jan 07, 2026, 9:37 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $93.48
Real-time Price: $20.51 info
Change: -$72.97 (-78%) info
Market Cap: $202.295M info
DRUG
Jan 07, 2026, 5:27 PM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $95.00
Real-time Price: $20.51 info
Change: -$74.49 (-78%) info
Market Cap: $202.295M info
DRUG
Jan 07, 2026, 3:16 PM EST
Filing Type: FWP
Importance Score:
9
Price at Filing: $95.00
Real-time Price: $20.51 info
Change: -$74.49 (-78%) info
Market Cap: $202.295M info
DRUG
Jan 06, 2026, 9:55 PM EST
Filing Type: FWP
Importance Score:
9
Price at Filing: $87.00
Real-time Price: $20.51 info
Change: -$66.49 (-76%) info
Market Cap: $202.295M info
DRUG
Jan 06, 2026, 9:54 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $87.00
Real-time Price: $20.51 info
Change: -$66.49 (-76%) info
Market Cap: $202.295M info
DRUG
Jan 06, 2026, 7:48 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $87.00
Real-time Price: $20.51 info
Change: -$66.49 (-76%) info
Market Cap: $202.295M info
DRUG
Jan 06, 2026, 5:27 PM EST
Filing Type: 6-K
Importance Score:
9
Price at Filing: $87.00
Real-time Price: $20.51 info
Change: -$66.49 (-76%) info
Market Cap: $202.295M info
DRUG
Jan 05, 2026, 5:26 PM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $86.75
Real-time Price: $20.51 info
Change: -$66.25 (-76%) info
Market Cap: $202.295M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets